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Abstract The differential diagnosis between primary uveal
melanoma and cutaneous melanoma metastasis in the eye
may be difficult, both clinically and histologically. We
report successful application of combined mutational
analysis of the NRAS and the CDKN2A gene to discriminate
between these two entities. The patient had a history of a
superficial spreading cutaneous melanoma of the left
shoulder. Nine years later, she developed a lymph node
metastasis in the left axilla, and 13 years later she presented
with an atypical, pigmented tumor in the uvea. Histologi-
cally, the origin of the uveal melanoma could not be
determined with certainty. We performed molecular analy-
sis on the skin melanoma, the lymph node metastasis and
the uveal melanoma. We detected an NRAS codon 61
mutation (c.182A>G, p.Gln61Arg) in all three tumor
specimens. This mutation was absent in the normal control
tissue of the patient, thereby excluding a germline mutation.
To confirm a clonal relationship between the tumors, we
also performed CDKN2A mutational analysis. We detected
a CDKN2A mutation ((p16) c.238C>T, p.Arg80X, (p14)
c.404C>T, p.Pro135Leu)) in the tumor samples, but not in
the normal control tissue of the patient. We concluded that
the uveal melanoma is a metastasis from the cutaneous
melanoma removed 13 years before.
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Introduction
Especially in case of two cutaneous melanomas or a
combination of an ocular and cutaneous melanoma, the
clinical and histological differential diagnosis between a
second primary melanoma and a melanoma metastasis can
be very difficult, as both organs show a relative high
frequency of primary melanomas. The commonest primary
intraocular malignancy of adults is uveal melanoma [10].
Metastatic melanoma to the eye is rare and generally occurs
in patients with widespread metastatic disease [17]. The
most common site of metastatic cutaneous melanoma
involvement of the eye is the choroid (46%). Metastatic
melanoma to the vitreous and anterior chamber is rare (11–
18% of all intraocular cutaneous melanoma metastases) [6].
Differentiation between a primary uveal melanoma and an
intraocular metastasis is of prognostic and clinical impor-
tance, as intraocular metastases imply systemic spread and
have a poor prognosis with a patient survival rarely
exceeding more than 1 year [17].
Mutations in BRAF and less frequently in NRAS are
involved in cutaneous melanoma development [4, 11]. In
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contrast, in primary uveal melanomas, BRAF and NRAS do
not appear to be involved in tumorigenesis [3, 8, 15].
CDKN2A mutations have been detected in cutaneous
melanoma, both in sporadic melanoma and especially in
familial melanoma, with frequencies ranging up to 30% for
the latter [16]. Both in primary sporadic ocular melanoma
and in familial cases of primary uveal melanoma, CDKN2A
mutations are very rarely detected (5%) [9, 14].
We present a case of a rare and relatively late occurrence
of an intraocular melanoma metastasis 13 years after
development of a primary cutaneous melanoma, and
illustrate the diagnostic use of RAS and CDKN2A mutational
analysis.
Clinical history
In November 2005, a 47-year-old caucasian female pre-
sented to her local ophthalmologist because of mouches
volantes in her left eye. She had a history of a superficial
spreading cutaneous melanoma of the left shoulder (Clark
level IV) removed in 1994, and a lymph node metastasis in
the left axilla excised in 2003. Since then no systemic
metastasis was detected at annual control. Visual acuity was
20/20 in both eyes and the vitreous of the left eye showed
some opacities. These opacities increased gradually over a
2-month period, but resolved spontaneously thereafter. In
July 2006, she again developed complaints of recurrent
mouches volantes. The diagnosis revealed uveitis, and the
patient was treated with local steroids. However, local
treatment was not effective and the patient was referred to
our center. Examination of the right eye revealed no
abnormalities. The visual acuity in the left eye was 20/40,
and non-pigmented cells were noticed in the anterior
chamber, along with a vitreous haze. As an extensive
uveitis screening revealed no abnormalities, intraocular
metastasis of the cutaneous melanoma removed 13 years
earlier was suspected. A focal, white, and preretinal
condensation of vitreous cells developed within a few
weeks and some pigmented cells became visible in the
vitreous. Subsequently, the intraocular pressure increased to
25 mmHg due to non-pigmented cells in the anterior
chamber. A diagnostic vitrectomy was performed. Vitreous
samples were positive for malignant melanoma cells. A
total body examination excluded systemic metastasis
outside the eye. Progressive worsening of the condition of
the left eye turned into a visual acuity of 20/80 and a
secondary glaucoma up to 50 mmHg occurred, refractive to
topical medication. On patient’s request, no eye salvaging
treatment such as external beam radiation was performed,
and the affected eye was enucleated. Histological examina-
tion of the eye ball revealed an atypical melanocytic lesion
in the iris and ciliary body, with extension under the retina
and invasion of the sclera. Although histologically the
growth pattern was consistent with primary uveal melanoma,
an intraocular metastasis could not be excluded with
certainty. As discrimination between second primary and
metastatic melanoma was of prognostic importance, we
decided to perform mutational analysis for the BRAF, NRAS,
HRAS, and CDKN2A genes on all tumor samples, as well as
on the normal control skin of this patient.
Materials and methods
BRAF, NRAS, and HRAS mutational analysis
DNA isolation was performed as previously described [1,
2]. Briefly, of all tissue samples about three 10-μm
unstained sections of formalin-fixed paraffin-embedded
Table 1 Primers used in the analysis of CDKN2A, BRAF, NRAS and HRAS, and the size of their PCR products
Exon Forward Reverse Size PCR product (bp)
CDKN2A (INK4a-ARF)*
1B TCAGGGAAGGCGGGTGCGCG GCCGCGGGATGTGAACCAC 244
1B CGCCGCGAGTGAGGGTTTT CACCGCGGTTATCTCCTCC 263
1A GAGAGGGGGAGAGCAGGCAG GCACCTCCTCTACCCGACC 122
1A GGAGCAGCATGGAGCCTTC AGTCGCCCGCCATCCC CTG 177
2 AGCTTCCTTTCCGTCATGC GCAGCACCACCAGCGTGTC 202
2 AGCCCAACTGCGCCGACCC CCAGGTCCACGGGCAGACG 146
2 TGGACGTGCGCGATGCCTG GGAAGCTCTCAGGGTACAAATTC 188
3 CGGTAGGGACGGCAAGAGAG GAGGGACCTTCGGTGACTGATG 162
BRAF* exon 15 CCTTTACTTACTACACCTCAG AAAAATAGCCTCAATTCTTAC 197
NRAS* exon 2 GGTTTCCAACAGGTTCTTGC TGGGTAAAGATGATCCGACA 240
NRAS* exon 3 GATTCTTACAGAAAACAAGTGG TAATGCTCCTAGTACCTGTAGAG 230
HRAS* exon 3 CTGCAGGATTCCTACCGGA ACTTGGTGTTGTTGATGGCA 196
*All forward primers contained the M13 consensus sequence TGT AAA ACG ACG GCC AGT at the 5′ end. All reverse primers contained the
M13 consensus sequence CAG GAA ACA GCT ATG ACC.
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tissue were manually microdissected, using H&E stained
sections as a reference. The tumor cell percentage in the
microdissected specimens was estimated as 70% for the
cutaneous and uveal melanoma and as 90% for the lymph
node metastasis. DNA was purified using the DNeasy
Blood and Tissue kit (Qiagen). Primer sequences are shown
in Table 1. Polymerase chain reaction (PCR) amplification
of BRAF exon 15, NRAS exons 2 and 3, and HRAS exon 3
was performed in a total volume of 50-μl PCR mix
containing 50 ng template DNA, 5 μl PCR buffer IV
(Integro), 10 μl dNTP 0.2 mM, 6.0 μl MgCl2 3.0 mM,
0.125 μl Taq DNA polymerase (Integro, 5 U/μl), and
22.9 μl mQ. An initial denaturation at 92°C for 5 min was
followed by 35 cycles of denaturation at 94°C for 45 s,
annealing at 60°C for 45 s, and extension at 72°C for 45 s with
a final extension of 5 min at 72°C. DNA amplification was
performed in a MJ PTC 200 PCR cycler (Biozym). After
purification of the PCR products using a Qiaquick PCR
purification kit (Qiagen), sequence analysis was performed
using BigDye terminator version 2 of Applied Biosystems on
an ABI 3730 automatic sequencer (Applied Biosystems).
CDKN2A mutational analysis
The CDKN2A mutation analysis was performed as previ-
ously described [1, 2]. Briefly, PCR was performed with
AmpliTaq Gold DNA Polymerase (Applied Biosystems)
using an optimized MgCl2 concentration (varying from 1 to
2 mM) in a MJ PTC 200 PCR cycler (Biozym). All primers
used in the analysis contained either an M13 forward or
M13 reverse consensus sequence. All primers and sizes of
the PCR products are listed in Table 1. The entire open
reading frames of CDKN2Awere analyzed in DNA isolated
from the tumor samples and normal skin.
Results
Revision of the primary cutaneous melanoma removed in
1994 revealed an asymmetric compound melanocytic lesion
with focal ulceration and lack of maturation toward the base
of the lesion. The melanocytes showed an epithelioid
phenotype with anisokaryosis and prominent nucleoli. Deep
mitotic figures were present (Fig. 1). A satellite lesion was
present at the junction of the dermis toward the subcutis.
Tumor thickness measured 1.5 mm, not including the
satellite. Focally, a preexistent nevus was present. Resection
margins were at least 2 mm free of tumor. Revision of the
lymph node metastasis in the left axilla that was excised in
2003 revealed a large tumor surrounded by limited
preexistent lymphoid tissue. The tumor cells showed
morphological resemblance to the cutaneous melanoma
cells with an epithelioid phenotype and frequent mitotic
figures. In addition, in the lymph node metastasis large
areas of necrosis were present.
Histological examination of the eye ball revealed an
atypical melanocytic lesion in the iris and ciliary body, with
extension under the retina and invasion of the sclera. Tumor
cells were also present at the surface of the ciliary body in
the anterior angle, and showed invasion in the area
containing the canal of Schlemm (Fig. 1). The melanocytic
cells showed an epithelioid morphology, with focally
spindle cell pattern, marked pleiomorphism of tumor cell
nuclei, and occasional mitotic figures. Tumor thickness
measured 3 mm.
Molecular analysis of the NRAS gene revealed a codon
61 mutation (c.182A>G, p.Gln61Arg) in all three tumor
Fig. 1 a. The cutaneous melanoma in 1994 was a superficial
spreading melanoma, Breslow thickness 1.5 mm, growing into the
reticular dermis (hematoxylin and eosin staining, original magnifica-
tion ×50). The inset shows a detail of the deep portion of the tumor
with epithelioid melanocytes, melanin pigment, and mitotic figure
(arrow, original magnification ×400). b. The intraocular melanoma,
located in the ciliary body and iris with invasion of the sclera, anterior
angle (asterisk) and canal of Schlemm (arrow) (hematoxylin and eosin
staining, original magnification ×50)
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Fig. 2 NRAS exon 3 mutation,
c.182A>G, p.Gln61Arg,
detected in the primary cutane-
ous melanoma, the lymph node
metastasis and the uveal
melanoma. Reverse sequence
Fig. 3 CDKN2A exon 2 muta-
tion, (p16) c.238C>T, p.
Arg80X; (p14) c.404C>T,
p.Pro135Leu, detected in the
primary cutaneous melanoma,
the lymph node metastasis and
the uveal melanoma. Forward
sequence
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samples. This mutation was not present in the normal
control skin of the patient (Fig. 2). No mutations were
detected in NRAS exon 2, BRAF exon 15, and HRAS exon
3. We also performed CDKN2A mutational analysis on all
samples. A CDKN2A mutation ((p16)c.238C>T, p.Arg80X,
(p14)c.404C>T, p.Pro135Leu)) was present in all three
tumor samples, but absent in the normal control tissue of
the patient, indicating that this is a somatic mutation
(Fig. 3). It was concluded that the ocular melanoma should
be considered as a metastasis of the cutaneous melanoma
diagnosed 13 years before.
Discussion
This case report illustrates that molecular analysis can be
very helpful in the differential diagnosis between a second
primary melanoma and a melanoma metastasis. We chose
for mutational analysis of the BRAF gene and the RAS proto-
oncogenes NRAS and HRAS, because these genes are
frequently involved in cutaneous melanocytic lesions, with
a reported total mutation frequency for NRAS or BRAF of
82% in cutaneous melanoma [4]. Furthermore, these
mutations are described to occur early in tumorigenesis,
before the development of metastasis [4, 11]. We detected
in all three tumor samples an NRAS codon 61 mutation
(c.182A>G, p.Gln61Arg). NRAS mutations are known to
occur in up to 30% of all cutaneous melanoma cases, the
most common being mutations in NRAS codon 61 [4, 7,
11]. In contrast, NRAS mutations have been reported to be
absent in primary uveal melanoma [3, 15]. The NRAS
mutation thus strongly supports the metastatic nature of the
intraocular melanoma in our patient. The finding of the
same somatic mutation in CDKN2A in both cutaneous and
intraocular melanoma confirms the metastatic nature of the
disease in this patient. In contrast to NRAS mutations that
are limited to codon 61 and codon 12 in cutaneous
melanoma, somatic CDKN2A mutations are much more
tumor specific and thus are not expected to be identical in
two different primary melanomas [7]. Furthermore, activating
CDKN2A mutations are described to be very rare in primary
ocular melanomas [9, 13].
Eskandarpour et al. reported specific activating mutations
in NRAS codon 61 in 95% of primary hereditary cutaneous
melanomas (20/21), but in only 10% of sporadic cutaneous
melanomas (1/10) [5]. Therefore, the presence of a somatic
NRAS codon 61 mutation might indicate a familial predis-
position to melanoma instead of a clonal relationship.
Discriminating between a second primary intraocular
melanoma and metastatic disease is of prognostic impor-
tance. Intraocular metastases of melanoma are associated
with a poor prognosis with a mean interval between
diagnosis of the intraocular metastasis and death of
8.8 months [17]. In contrast, survival in patients diagnosed
with a primary intraocular melanoma is more variable, with
a reported 5-year cumulative survival rate of up to 60%
[12].
In conclusion, this case report illustrates that mutational
analysis for the RAS proto-oncogenes and CDKN2A can be
useful in the clinically relevant, but sometimes difficult,
differential diagnosis between a second primary intraocular
melanoma and an intraocular metastasis of a cutaneous
melanoma.
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